Literature DB >> 9829556

In vitro chromosome aberration assay using human bronchial epithelial cells.

B H Lee1, S J Lee.   

Abstract

The determination of chromosome aberrations (CA) in Chinese hamster lung fibroblast (CHL) cells was compared with that in normal human bronchial epithelial (BEAS-2B) cells, which upon adenovirus infection were reported to possess carcinogen metabolizing capacities similar to polycyclic aromatic hydrocarbons. CHL and BEAS-2B cells were treated with increasing concentrations of benzo[a]pyrene (BaP) or N-nitrosodiethylamine (NDEA). In BEAS-2B cells, BaP, at a concentration of 50 microg/ml, produced a significant increase in the CA frequency, while NDEA did not markedly alter the number of aberrations in the absence of S9 mixture. The CHL cells exposed to BaP and NDEA in the presence of S9 mixture responded as anticipated with a 30% and 14% frequency of CA observed in the BaP (50 microg/ml) and NDEA (1000 microg/ml) treated cells, respectively. The results of this study show that the CA assay using human cell line with intrinsic metabolic activation system, such as BEAS-2B cells, may be a useful model for predicting human clastogens and carcinogens.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9829556     DOI: 10.1080/009841098158377

Source DB:  PubMed          Journal:  J Toxicol Environ Health A        ISSN: 0098-4108


  2 in total

Review 1.  Biomarkers of chromosomal damage in peripheral blood lymphocytes induced by polycyclic aromatic hydrocarbons: a meta-analysis.

Authors:  Yadong Wang; Haiyan Yang; Li Li; Haiyu Wang; Xiangqun Xia; Congke Zhang
Journal:  Int Arch Occup Environ Health       Date:  2011-04-02       Impact factor: 3.015

2.  Clinical trial considerations on male contraception and collection of pregnancy information from female partners.

Authors:  Maria Longauer Banholzer; Heinrich Buergin; Christoph Wandel; Georg Schmitt; Elmar Gocke; Richard Peck; Thomas Singer; Theresa Reynolds; Marie Mannino; Jonathan Deutsch; Lucette Doessegger
Journal:  J Transl Med       Date:  2012-06-21       Impact factor: 5.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.